Therapeutic Strategies for MASH: An Update on Drug Candidates Under Investigation in Late-Phase Clinical Trials Samuel Dinerman, Yan Shu International Journal of Translational Medicine.2025; 5(1): 7. CrossRef
Identification of Novel Therapeutic Targets for MAFLD Based on Bioinformatics Analysis Combined with Mendelian Randomization Jialin Ren, Min Wu International Journal of Molecular Sciences.2025; 26(7): 3166. CrossRef
Inflammation in MASLD progression and cancer Yeonsoo Kim, Yunseo Park, Hyunsoo Rho, Tiantian Yao, Bin Gao, Seonghwan Hwang JHEP Reports.2025; 7(8): 101414. CrossRef
Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma Young-Min Jee, Jeong-Yoon Lee, Tom Ryu Biomedicines.2025; 13(5): 1260. CrossRef
Isolation and Characterization of Secondary Metabolites from Hydractinia-Associated Fungus, Penicillium brevicompactum MSW10-1, and Their Inhibitory Effects on Hepatic Lipogenesis Hyeon-Jeong Hwang, Hyeokjin Lim, Jae Sik Yu, Eun Seo Jang, Youngsang Nam, Yeo Jin Lee, Eun La Kim, Seonghwan Hwang, Seoung Rak Lee Marine Drugs.2025; 23(7): 275. CrossRef
Nanomedicines in the Treatment of Liver Fibrosis: A Review Xiao Du, Runyan Niu, Xuexue Liu, Fang Wu, Xian Yang, Xiaolong Ma, Jinping Zhang, Haihui Zhou, Lihua Shao, Siliang Wang International Journal of Nanomedicine.2025; Volume 20: 9641. CrossRef
Targeting Stearoyl-CoA Desaturase-1 (SCD1) by the Drug–Nutraceutical Combination of Montelukast and Bixin in Ameliorating Steatotic NAFLD Sonakshi Puri, Shivani Kirad, Shubhashree Dash, Pankaj Kumar Sharma, Murugesan Sankaranarayanan, Perinkulam Ravi Deepa ACS Omega.2025; 10(40): 47022. CrossRef
Physicochemical characterization, lipid-modulating effects, and proteomic insights of Malaysian Sacha Inchi (Plukenetia volubilis L.) seed oil in HepG2 cells Mariam Fardush, Norsyahida Mohd Fauzi, Ho Wen Yan, Armania Nurdin, Ibrahim Jantan, Nor Azlan bin Nor Muhammad, Siti Nurlisa Hazim, Sarmila Hanim binti Mustafa, Kimberlyn Feguro Food Bioscience.2025; 74: 107891. CrossRef
Redox Modulation in Hepatic Fibrosis: Translating NOX1/4 Inhibition to Therapy Ghaith K. Mansour, Ahmad W. Hajjar, Irene Marafini, Giovanni Monteleone International Journal of Molecular Sciences.2025; 27(1): 158. CrossRef
Inhibition of sodium-glucose cotransporter-2 and liver-related complications in individuals with diabetes: a Mendelian randomization and population-based cohort study Sung Won Chung, Hye-Sung Moon, Hyunjae Shin, Hyein Han, Sehoon Park, Heejin Cho, Jeayeon Park, Moon Haeng Hur, Min Kyung Park, Sung-Ho Won, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Dong Ki Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Yoon Jun Kim Hepatology.2024; 80(3): 633. CrossRef
Effectiveness of the ALT/AST ratio for predicting insulin resistance in a Korean population: A large-scale, cross-sectional cohort study Seul Ki Han, Myung Jae Seo, Taesic Lee, Moon Young Kim, Anna Di Sessa PLOS ONE.2024; 19(5): e0303333. CrossRef
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis Renuka Suvarna, Sahana Shetty, Joseph M. Pappachan Scientific Reports.2024;[Epub] CrossRef
Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease Ana Paula Madariaga Traconis, Misael Uribe-Esquivel, Varenka Julieta Barbero Becerra Cells.2024; 13(24): 2055. CrossRef
First
Prev
